Richard Collin to Leave IBEX Technologies Inc. as Director of Finance, Effective September 3, 2020

IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.’s primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISA’s) for pre-clinical research. The Company has developed a proprietary expression for the production of its enzymes in Flavobacterium heparinum. This expression system allows for producing each glycosaminoglycan (GAG) enzyme separately from other enzymes therefore achieving the highest purity using a well-defined proprietary purification scheme. The Company operates in one industry segment: the production and sale of diagnostic products.